Positive feedback loops drive immune cell polarization toward a pro-tumor phenotype that accentuates immunosuppression and tumor angiogenesis. This phenotypic switch leads to the escape of cancer cells from immune destruction. These positive feedback loops are generated by cytokines such as TGF-β, Interleukin-10 and Interleukin-4, which are responsible for the polarization of monocytes and M1 macrophagesinto pro-tumor M2 macrophages, and the polarization of naive helper T cells intopro-tumor Th2 cells. In this article, we present a deterministic ordinary differential equation (ODE) model that includes key cellular interactions and cytokine signaling pathways that lead to immune cell polarization in the tumor microenvironment. The model was used to simulate various cancer treatments in silico. We identified combination therapies that consist of M1 macrophages or Th1 helper cells,coupled with an anti-angiogenic treatment, that are robust with respect to immune response strength, initial tumor size and treatment resistance. We also identified IL-4 and IL-10 as the targets that should be neutralized in order to make these combination treatments robust with respect to immune cell polarization. The model simulations confirmed a hypothesis based on published experimental evidence that a polarization into the M1 and Th1 phenotypes to increase the M1-to-M2 and Th1-to-Th2 ratios plays a significant role in treatment success. Our results highlight the importance of immune cell reprogramming as a viable strategy to eradicate a highly vascularized tumor when the strength of the immune response is characteristically weak and cell polarization to the pro-tumor phenotype has occurred.
References
[1]
Andersen, M.H. (2015) Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. Journal of the National Cancer Institute, 107, djv154-djv154. https://doi.org/10.1093/jnci/djv154
[2]
Nouroz, F., Bibi, F., Noreen, S. and Masood, N. (2016) Natural Killer Cells Enhance the Immune Surveillance of Cancer. The Egyptian Journal of Medical Human Genetics, 17, 149-154. https://doi.org/10.1016/j.ejmhg.2015.08.006
[3]
Zhang, M.m et al. (2014) A high M1/M2 Ratio of Tumor-Associated Macrophages Is Associated with Extended Survival in Ovarian Cancer Patients. Journal of Ovarian Research, 7, 19. https://doi.org/10.1186/1757-2215-7-19
[4]
Den Breems, N.Y. and Eftimie, R. (2016) The Re-Polarisation of M2 and M1 Macrophages And Its Role on Cancer Outcomes. Journal of Theoretical Biology, 390, 23-39. https://doi.org/10.1016/j.jtbi.2015.10.034
[5]
Bergmann, C., Van Hemmen, J.L. and Segel, L.A. (2001) Th1 or Th2: How an Appropriate T Helper Response Can Be Made. Bulletin of Mathematical Biology, 63, 405-431. https://doi.org/10.1006/bulm.2000.0215
[6]
Kogan, Y., Agur, Z. and Elishmereni, M. (2013) A Mathematical Model for the Immunotherapeutic Control of the Th1/Th2 Imbalance in Melanoma. Discret. Contin. Dyn. Syst. - Ser. B, 18, 1017-1030.
[7]
Shurin, M.R., Lu, L., Kalinski, P., Stewart-Akers, A.M. and Lotze, M.T. (1999) Th1/Th2 Balance in Cancer, Transplantation and Pregnancy. Springer Seminars In immunopathology, 21, 339-359. https://doi.org/10.1007/BF00812261
[8]
Wang, X.L., et al. (2017) High Infiltration of CD68-Tumor Associated Macrophages, Predict Poor Prognosis in Kazakh Esophageal Cancer Patients. International Journal of Experimental Pathology, 10, 10282-10292.
[9]
Yafei, Z., Jun, G. and Guolan, G. (2016) Correlation between Macrophage Infiltration and Prognosis of Ovarian Cancer—A Preliminary Study. Biomedical Research, 27, No. 2.
[10]
Tanaka, A. and Sakaguchi, S. (2017) Regulatory T Cells in Cancer Immunotherapy. Cell Research, 27, 109-118. https://doi.org/10.1038/cr.2016.151
[11]
Tosolini, M., et al. (2011) Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, th2, treg, th17) in Patients with Colorectal Cancer. Cancer Research, 71, 1263-1271. https://doi.org/10.1158/0008-5472.CAN-10-2907
[12]
Zheng, X., et al. (2017) Redirecting Tumor-Associated Macrophages to Become Tumoricidal Effectors as a Novel Strategy for Cancer Therapy. Oncotarget, 8, 48436-48452. https://doi.org/10.18632/oncotarget.17061
[13]
Genard, G., Lucas, S. and Michiels, C. (2017) Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Frontiers in Immunology, 8, 828.
https://doi.org/10.3389/fimmu.2017.00828
[14]
Fridlender, Z.G., et al. (2013) Using Macrophage Activation to Augment Immunotherapy of Established Tumours. British Journal of Cancer, 108, 1288-1297.
https://doi.org/10.1038/bjc.2013.93
[15]
Brown, J.M., Recht, L. and Strober, S. (2017) The Promise of Targeting Macrophages in Cancer Therapy. Clinical Cancer Research, 23, 3241-3250.
https://doi.org/10.1158/1078-0432.CCR-16-3122
[16]
Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity, 41, 49-61.
https://doi.org/10.1016/j.immuni.2014.06.010
[17]
La Flamme, A.C., Kharkrang, M., Stone, S., Mirmoeini, S., Chuluundorj, D. and Kyle, R. (2012) Type II-Activated Murine Macrophages Produce IL-4. PLoS One, 7, e46989. https://doi.org/10.1371/journal.pone.0046989
[18]
Neurath, M.F., Fichtner-Feigl, S. and Kesselring, R. (2015) Intestinal Inflammation and Cancer of the Gastrointestinal Tract. In: Mucosal Immunology, Elsevier, Amsterdam, 1761-1775. https://doi.org/10.1016/B978-0-12-415847-4.00091-4
[19]
Romagnani, S. (1992) Type 1 T Helper and Type 2 T Helper Cells: Functions, Regulation and Role in Protection and Disease. International Journal of Clinical and Laboratory Research, 21, 152-158. https://doi.org/10.1007/BF02591635
[20]
Chen, W., et al. (2003) Conversion of Peripheral CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-Beta Induction of Transcription Factor Foxp3. Journal of Experimental Medicine, 198, 1875-1886.
https://doi.org/10.1084/jem.20030152
[21]
Mitrophanov, A.Y. and Groisman, E.A. (2008) Positive Feedback in Cellular Control Systems. Bioessays, 30, 542-555. https://doi.org/10.1002/bies.20769
[22]
Ingolia, N.T. and Murray, A.W. (2007) Positive-Feedback Loops as a Flexible Biological Module. Current Biology, 17, 668-677.
https://doi.org/10.1016/j.cub.2007.03.016
[23]
Burkholder, B., et al. (2014) Tumor-Induced Perturbations of Cytokines and Immune Cell Networks. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1845, 182-201. https://doi.org/10.1016/j.bbcan.2014.01.004
[24]
Fernandez, M., Zhou, M. and Soto-Ortiz, L. (2018) A Computational Assessment of the Robustness of Cancer Treatments with Respect to Immune Response Strength, Tumor Size and Resistance. International Journal of Tumor Therapy, 7, 1-19.
[25]
Sameen, S., Barbuti, R., Milazzo, P., Cerone, A., Del Re, M. and Danesi, R. (2016) Mathematical Modeling of Drug Resistance Due to KRAS Mutation in Colorectal Cancer. Journal of Theoretical Biology, 389, 263-273.
https://doi.org/10.1016/j.jtbi.2015.10.019
[26]
Jounaidi, Y., Cotten, J.F., Miller, K.W. and Forman, S.A. (2017) Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells. Cancer Research, 77, 5938-5951.
https://doi.org/10.1158/0008-5472.CAN-17-1007
[27]
Kim, H., Kwon, B. and Sin, J.-I. (2013) Combined Stimulation of IL-2 and 4-1BB Receptors Augments the Antitumor Activity of E7 DNA Vaccines by Increasing Ag-Specific CTL Responses. PLoS One, 8, e83765.
https://doi.org/10.1371/journal.pone.0083765
[28]
Liu, C., Workman, C.J. and Vignali, D.A.A. (2016) Targeting Regulatory T Cells in Tumors. The FEBS Journal, 283, 2731-2748. https://doi.org/10.1111/febs.13656
[29]
Martinez, F.O. and Gordon, S. (2014) The M1 and M2 Paradigm of Macrophage Activation: Time for Reassessment. F1000 Prime Reports, 6, 13.
https://doi.org/10.12703/P6-13
[30]
Magombedze, G., Reddy, P.B.J., Eda, S. and Ganusov, V.V. (2013) Cellular and Population Plasticity of Helper CD4+ T Cell Responses. Frontiers in Physiology, 4, 206. https://doi.org/10.3389/fphys.2013.00206
[31]
Hao, W., Schlesinger, L.S. and Friedman, A. (2016) Modeling Granulomas in Response to Infection in the Lung. PLoS One, 11, e0148738.
https://doi.org/10.1371/journal.pone.0148738
[32]
de Pillis, L.G., Savage, H. and Radunskaya, A.E. (2014) Mathematical Model of Colorectal Cancer with Monoclonal Antibody Treatments. British Journal of Medicine and Medical Research, 4, No. 16.
[33]
Kim, K.S., Cho, G. and Jung, I.H. (2014) Optimal Treatment Strategy for a Tumor Model under Immune Suppression. Computational and Mathematical Methods in Medicine, 2014, 206287. https://doi.org/10.1155/2014/206287
[34]
Del Monte, U. (2009) Does the Cell Number 10(9) Still Really Fit one Gram of Tumor Tissue? Cell Cycle, 8, 505-506. https://doi.org/10.4161/cc.8.3.7608
[35]
Whiteside, T.L. (2010) Inhibiting the Inhibitors: Evaluating Agents Targeting Cancer Immunosuppression. Expert Opinion on Biological Therapy, 10, 1019-1035.
https://doi.org/10.1517/14712598.2010.482207
[36]
Facciabene, A., Motz, G.T. and Coukos, G. (2012) T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. Cancer Research, 72, 2162-2171.
https://doi.org/10.1158/0008-5472.CAN-11-3687
[37]
Neuzillet, C., et al. (2015) Targeting the TGFβ Pathway for Cancer Therapy. Pharmacology & Therapeutics, 147, 22-31.
https://doi.org/10.1016/j.pharmthera.2014.11.001
[38]
Niu, G. and Chen, X. (2010) Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy. Current Drug Targets, 11, 1000-1017.
https://doi.org/10.2174/138945010791591395
[39]
Carmeliet, P. (2005) VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology, 69, 4-10. https://doi.org/10.1159/000088478
[40]
Asadullah, K., Sterry, W. and Volk, H.D. (2003) Interleukin-10 Therapy—Review of a New Approach. Pharmacological Reviews, 55, 241-269.
https://doi.org/10.1124/pr.55.2.4
[41]
Wang, L., Liu, J.-Q., Talebian, F., Liu, Z., Yu, L. and Bai, X.-F. (2015) IL-10 Enhances CTL-Mediated Tumor Rejection by Inhibiting Highly Suppressive CD4+T Cells and Promoting CTL Persistence in a Murine Model of Plasmacytoma. Oncoimmunology, 4, e1014232.
[42]
Oft, M. (2014) IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. Cancer Immunology Research, 2, 194-199.
https://doi.org/10.1158/2326-6066.CIR-13-0214
[43]
Morris, J.C., et al. (2014) Phase I study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. PLoS One, 9, e90353.
https://doi.org/10.1371/journal.pone.0090353
[44]
Ishida, H., Muchamuel, T., Sakaguchi, S., Andrade, S., Menon, S. and Howard, M. (1994) Continuous Administration of Anti-Interleukin 10 Antibodies Delays Onset of Autoimmunity in NZB/W F1 Mice. The Journal of Experimental Medicine, 179, 305-310. https://doi.org/10.1084/jem.179.1.305
[45]
DePillis, L., Caldwell, T., Sarapata, E. and Williams, H. (2013) Mathematical Modeling of Regulatory T Cell Effects on Renal Cell Carcinoma Treatment. Discret. Contin. Dyn. Syst. - Ser. B, 18, 915-943.
[46]
Sakamoto, N., et al. (2015) Phase I Clinical Trial of Autologous NK Cell Therapy Using Novel Expansion Method in Patients with Advanced Digestive Cancer. Journal of Translational Medicine, 13, 277. https://doi.org/10.1186/s12967-015-0632-8
[47]
Kronik, N., Kogan, Y., Vainstein, V. and Agur, Z. (2008) Improving Alloreactive CTL Immunotherapy for Malignant Gliomas Using a Simulation Model of Their Interactive Dynamics. Cancer Immunology, Immunotherapy, 57, 425-439.
https://doi.org/10.1007/s00262-007-0387-z
[48]
Rosenberg, S.A. (2014) IL-2: The First Effective Immunotherapy for Human Cancer. The Journal of Immunology, 192, 5451-5458.
https://doi.org/10.4049/jimmunol.1490019
[49]
de Pillis, L., et al. (2009) Mathematical Model Creation for Cancer Chemo-Immunotherapy. Computational and Mathematical Methods in Medicine, 10, 165-184. https://doi.org/10.1080/17486700802216301
[50]
Arciero, J.C., Jackson, T.L. and Kirschner, D.E. (2004) A Mathematical Model of Tumor-Immune Evasion and siRNA Treatment. Discret. Contin. Dyn. Syst. - Ser. B, 4, 39-58.
[51]
Robertson-Tessi, M., El-Kareh, A. and Goriely, A. (2012) A Mathematical Model of Tumor-Immune Interactions. Journal of Theoretical Biology, 294, 56-73.
https://doi.org/10.1016/j.jtbi.2011.10.027
[52]
Bian, X., et al. (2006) Increased Angiogenic Capabilities of Endothelial Cells from Microvessels of Malignant Human Gliomas. International Immunopharmacology, 6, 90-99. https://doi.org/10.1016/j.intimp.2005.08.004
[53]
Hahnfeldt, P., Panigrahy, D., Folkman, J. and Hlatky, L. (1999) Tumor Development under Angiogenic Signaling: A Dynamical Theory of Tumor Growth, Treatment Response, and Postvascular Dormancy. Cancer Research, 59, 4770-4775.
[54]
Mabarrack, N.H.E., Turner, N.L. and Mayrhofer, G. (2008) Recent Thymic Origin, Differentiation, and Turnover of Regulatory T Cells. Journal of Leukocyte Biology, 84, 1287-1297. https://doi.org/10.1189/jlb.0308201
[55]
Sun, X., et al. (2016) Mathematical Modeling of Therapy-Induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Scientific Reports, 6, 22498. https://doi.org/10.1038/srep22498
[56]
Cameron, M.A., Davis, A.L., Kostelich, E. and Eikenberry, S. (2009) A Mathematical Model of Angiogenesis in Glioblastoma Multiforme. Arizona State University, Tempe.
